Journals / Journal of Clinical and Analytical Medicine / 2014 / Cilt: 5 - Sayı: 1

Anjiyogenez ve anti-anjiyogenik tedaviler

Angiogenesis and anti-angiogenic treatments

Pages
75–79
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has been used in colorectal carcinoma, renal cell carcinoma, non-small cell lung cancer, glioblastoma, heoatocellular carcinoma, pancreatic neuroendocrine tumor, tyroid medullary cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Blood vessels in our body is developed by vasculogenesis and angiogenesis.
📊
Key Findings & Data:There have been new advances in molecular pathology and tumor biology areas in recent years.
💡
Conclusion & Impact:It has been used in colorectal carcinoma, renal cell carcinoma, non-small cell lung cancer, glioblastoma, heoatocellular carcinoma, pancreatic neuroendocrine tumor, tyroid medullary cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Blood vessels in our body is developed by vasculogenesis and angiogenesis. There have been new advances in molecular pathology and tumor biology areas in recent years. Angiogenesis is modulated by the balance between angiogenic and anti-angiogenic factors. Angiogenesis plays a key role in tumor growth. Drugs inhibiting angiogenesis have been in use in various malign or non-malign diseases. Inhibition of angiogenesis in malign diseases is a very attractive subject in medicine and studies are going on about long term affects and toxicities. Inhibition of angiogenesis is not an only treatment choice alone. It is a supplemental treatment option applied with conventional chemotherapy, radiotherapy, surgery, immunotherapy and hormonal therapy. It has been used in colorectal carcinoma, renal cell carcinoma, non-small cell lung cancer, glioblastoma, heoatocellular carcinoma, pancreatic neuroendocrine tumor, tyroid medullary cancer.

Özet

Vücudumuzdaki kan damarları vaskülogenez ve anjiyogenez yolları ile oluşmaktadır. Son yıllarda moleküler patoloji ve tümör biyolojisi alanlarında bir-çok yeni gelişmeler olmuştur. Anjiyogenik ve anti-anjiyogenik faktör arasındaki denge ile anjiyogenez düzenlenmektedir. Anjiyogenezin tümör büyümesinde anahtar bir rol oynamaktadır. Malign ve malign olmayan birçok hastalığın tedavisinde anjiyogenezi inhibe eden ilaçlar kullanılmaya başlamıştır. Tıpdünyasında malign hastalıklarda anjiyogenezin inhibisyonu çok ilgi çekmekte ve uzun dönem etkileri ve toksisiteleri araştırılmaktadır. Anjiyogenezin inhibisyonu tek başına bir tedavi seçeneği değildir. Konvansiyonel kemoterapi,radyoterapi, cerrahi, immunoterapi veya hormonal tedaviye destek vermektedir. Kolorektal kanser, renal hücreli karsinom, küçük hücreli dışı akciğer kanseri, glioblastoma, hepatosellüler karsinom, pankreatik nöroendokrin tümör,tiroid medüller kanser tedavilerinde kullanıma girmiştir.

🔖

Cite This Article

AYTEN, Ö., TAŞ, D., DEMİRER, E. (2022). Anjiyogenez ve anti-anjiyogenik tedaviler. Journal of Clinical and Analytical Medicine, Cilt: 5 - Sayı: 1, 75–79. https://ajindex.com/articles/561539

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-60
  2. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angio- genesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003;95(22):1660-73
  3. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008;143(5):622-31
  4. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6(7):395-404
  5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
  6. Erdem F, Gündoğdu M. Anjiojenesis ve anti-anjiojenik tedavi. AÜTD 2005;37(1):1-6
  7. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 2000;26(5):561-9
  8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
  9. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000;19(53):6122-9
  10. Özuysal S. Tümöral anjiogenezis. Türk Patoloji Dergisi 2001;17(3-4): 90-3
  11. Donnem T, Al-Saad S, Al Shibli K, Delghandi MP, Perrson M, Nilsen MN, et al. Inverse prognostic impact of angiogenetic marker expression in tumor cells versus stromal cells in non small cell lung canser. Clin Cancer Res 2007;13(1- 22):6649-57
  12. Van Meurs MJ, Kümpers P, Ligtenberg J, Meertens J, Molema G, Zijlestra JG. Bench-to-bedside review: Angiopoietin signalling in critical illness – a future target? Crit Care 2009;13(2):207
  13. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, et al. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intra- cellular signaling and cell survival. FASEB J 2007;21(12):3171–83
  14. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gerstenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyro- sine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8(16):1897-909
  15. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87(5):1171-80
  16. Sundberg C, Kowanetz M, Brown LF, Detmar M, Dvorak HF. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab